Cutaneous Ulceration Associated with Subcutaneous Interferon Beta 1a Injection
نویسندگان
چکیده
منابع مشابه
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
AIM Subcutaneous (s.c.) peginterferon beta-1a injected once every 2 weeks and s.c. interferon beta-1a injected three times per week (Rebif®) have demonstrated efficacy in relapsing-remitting multiple sclerosis, but direct comparisons of pharmacological activity and tolerability between the two products are lacking. COMPARE was an open label, crossover, pharmacokinetic (PK) study evaluating drug...
متن کاملHalo Nevi Associated With Interferon Beta-1a Therapy
The interferons are a group of more than 20 glycoproteins produced by numerous body cells in response to the presence of viruses, double-stranded RNA, polypeptides, or bacterial products. All of them share the ability to inhibit viral replication and cell proliferation, and to regulate and modulate immune cells. From an immunologic point of view, interferons increase the expression of class I o...
متن کاملHalo nevi associated with interferon beta-1a therapy.
The interferons are a group of more than 20 glycoproteins produced by numerous body cells in response to the presence of viruses, double-stranded RNA, polypeptides, or bacterial products. All of them share the ability to inhibit viral replication and cell proliferation, and to regulate and modulate immune cells. From an immunologic point of view, interferons increase the expression of class I o...
متن کاملInterferon beta-1a–induced morphea
IL-4: Interleukin 4 IFN-b: Interferon beta IFN-b1a: Interferon beta-1a MS: Multiple sclerosis SSc: Systemic sclerosis Th2: T helper 2 INTRODUCTION Interferon beta-1a (IFN-b1a) is a cytokine therapy used in the treatment of relapsing-remitting multiple sclerosis. The most common adverse injection site reactions include local erythema, pain, and induration. Other less frequently encountered react...
متن کاملSevere dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.
BACKGROUND Type I interferons (IFNs) are common therapeutics for several diseases, including viral infections and multiple sclerosis (MS). Although numerous studies have implicated type I INFs with the production of autoantibodies and the development of certain autoimmune disorders, interferon beta has not previously been described in association with dermatomyositis, to our knowledge. Previous...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Turkish Journal of Pediatric Disease
سال: 2018
ISSN: 1307-4490,2148-3566
DOI: 10.12956/tjpd.2018.336